STAT+: Stoke Therapeutics drug, targeting genetic cause of childhood epilepsy, reduces seizure activity
An experimental drug from Stoke Therapeutics reduced the frequency of convulsive seizures in children with a rare form of epilepsy called Dravet syndrome, the company said Friday.
The study results are early and far from conclusive, but show the potential for a novel, RNA-based treatment to target the underlying genetic cause of the devastating childhood disorder, said Stoke CEO Ed Kaye.
